Does Cucurbitacin E (CuE) exhibit cytotoxicity toward 3T3-L1 adipocytes during adipogenesis?

Label:chem

Topic
Many anti-obesity compounds can impair cell viability, so it is crucial to verify whether CuE affects cell survival.
Answer
No—MTT assays, annexin V/PI flow cytometry, and cell-cycle analyses showed that CuE (≤10 nM) neither reduced cell viability nor induced apoptosis, necrosis, or cell-cycle arrest in 3T3-L1 adipocytes.
Return to Home Chemical List
Knowledge you may be interested in
What is Cucurbitacin E (CuE) and where is it derived from? Is the antiviral activity of zinc ions maintained across physiologically relevant temperatures? Does zinc-mediated inactivation compromise the structural integrity of the IAV particle? How do zinc ions affect influenza A virus (IAV) hemagglutinin function and virus infectivity? What role does desloratadine or levocetirizine play when added to oral isotretinoin in the treatment of acne vulgaris? What evidence supports the efficacy of relugolix combination therapy in endometriosis? How do clinical outcomes compare between relugolix monotherapy and combination therapy? Does relugolix combination therapy preserve BMD over extended treatment periods? What strategy has been developed to mitigate relugolix-induced BMD loss? How does relugolix monotherapy affect bone mineral density (BMD)? How does CuE influence lipid accumulation in differentiating 3T3-L1 adipocytes? Which key adipogenic transcription factors are down-regulated by Cucurbitacin E (CuE)? What molecular pathways are implicated in CuE-mediated inhibition of adipogenesis and lipogenesis? What is the overall conclusion regarding CuE’s potential as an anti-obesity agent? What is the role of synthetic angiotensin II (Giapreza®/AT2S) in the peri-operative management of kidney transplantation? Were there any safety concerns specific to angiotensin II (Giapreza®/AT2S) use? What is nicotine's proposed mechanism of neuroprotection in Parkinson’s disease (PD)? What were the findings of the meta-analysis regarding nicotine's effect on motor symptoms in PD patients? Did nicotine therapy improve activities of daily living (ADLs), quality of life (QoL), or cognition in PD patients? What limitations were identified in the clinical trials evaluating nicotine therapy for PD?